Management of Rheumatoid Arthritis After Methotrexate-Induced Mucositis

Introduction to Alternative Treatment Options

The American College of Rheumatology conditionally recommends switching to a non-methotrexate DMARD over continuation of methotrexate for future management of rheumatoid arthritis in patients who develop mucositis due to methotrexate 1, 2

For patients with moderate-to-high disease activity who fail to respond to a single csDMARD, the European League Against Rheumatism recommends combination therapy with multiple csDMARDs, such as sulfasalazine plus hydroxychloroquine 3, 5
The American College of Rheumatology suggests that leflunomide is a preferred option due to its efficacy profile similar to MTX 2, 3
For patients with persistent moderate-to-high disease activity despite optimized csDMARDs, biologic DMARDs or targeted synthetic DMARDs should be added, according to the American College of Rheumatology 1, 4

The American Heart Association and the American College of Cardiology recommend avoiding TNF inhibitors and preferring non-TNF biologics or tsDMARDs in patients with heart failure 7, 2
The American College of Rheumatology suggests considering prophylactic antiviral therapy if using rituximab in patients with hepatitis B 7, 2
Biomarker-guided treatment selection may improve outcomes, with the presence of rheumatoid factor, anti-citrullinated protein antibodies, or elevated serum IgG predicting better response to rituximab, according to the Mayo Clinic 5, 4

The treatment algorithm recommends assessing disease activity after mucositis resolution, and starting hydroxychloroquine or sulfasalazine monotherapy for low disease activity, or leflunomide monotherapy for moderate-to-high disease activity 2, 4, 5
If inadequate response after 3 months, the algorithm suggests adding a second csDMARD, and if still inadequate response after 3 months of combination therapy, adding a bDMARD or tsDMARD 1, 3, 4, 5